FDA Requests Entereg Failed Study Data, Adolor Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Alvimopan failed to show statistical significance for the primary endpoint in partner GlaxoSmithKline’s Phase III study. The pending NDA for the postoperative ileus therapy is based on three studies with mixed results.